Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011–2019 oncology clinic electronic he
A Multiple Myeloma Roundtable: Treatment Trends and Recent Clinical Advances
Expression of interleukin-32 in bone marrow of patients with myeloma and its prognostic significance
Impact of Novel Therapies on Multiple Myeloma Survival– Current and Future Outcomes - Clinical Lymphoma, Myeloma and Leukemia
Mayo Clinic Rochester Publishes Updated Multiple Myeloma Survival Rates! - Multiple Myeloma - Survival Rate Statistics by Hospital
Improved long-term survival in multiple myeloma up to the age of 80 years | Leukemia
Cureus | Increased Risk of Second Primary Malignancy and Mortality at ten Years After Stem Cell Transplant for Multiple Myeloma: An Analysis of 14,532 Patients
Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes - Landgren - 2017 - Journal of Internal Medicine - Wiley Online Library
Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome | Blood Cancer Journal
Overall survival from diagnosis of multiple myeloma, according to world... | Download Scientific Diagram
Figure 1 from Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. | Semantic Scholar
Kaplan-Meier curves for overall survival for patients with genetic... | Download Scientific Diagram
![The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial - The](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2f9746ff-a56a-4d1f-9fa7-5e6b9f11a6ee/gr1_lrg.jpg "The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial - The")
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial - The
The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study | Atlantis Press
The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study | Atlantis Press
Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population - Clinical Lymphoma, Myeloma and Leukemia
Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France
Trends in overall survival and costs of multiple myeloma, 2000–2014 | Leukemia
Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience | Cancer Communications | Full Text
Daratumumab, Lenalinomide, and Dexamethasone for Myeloma | NEJM Resident 360
Disparities in Care and Outcomes
Progression-free and overall survival for high-risk patients with relapsed or refractory multiple myeloma (RRMM) who received carfilzomib-based regimens
Age-dependent overall survival of 2,907 newly diagnosed Danish patients... | Download Scientific Diagram
